180 Life Sciences Unternehmenswert
Was ist das Unternehmenswert von 180 Life Sciences?
Unternehmenswert von 180 Life Sciences Corp. ist $8.60M
Was ist die Definition von Unternehmenswert?
Der Unternehmenswert ist ein Maß für den gesamten Marktwert eines Unternehmens. Es wird als Marktkapitalisierung mit Verschuldung, Minderheitsanteilen und Vorzugsaktien abzüglich der Zahlungsmittel und Zahlungsmitteläquivalente berechnet.
It is a sum of claims by all claimants including creditors (secured and unsecured) and shareholders (preferred and common). Enterprise value is one of the fundamental metrics used in business valuation, financial modeling, accounting, portfolio analysis, and risk analysis. Enterprise value is more comprehensive than market capitalization, which only reflects common equity and is considered more representative of a company’s value. Enterprise value reflects the opportunistic nature of business and may change substantially over time because of both external and internal conditions.
Enterprise value can be negative if the company holds abnormally high amounts of cash that is not reflected in the market value of the stock and total capitalization. Cash is subtracted in the calculation because it reduces the net cost to a potential purchaser. The effect applies whether the cash is used to issue dividends or to pay down debt. Value of minority interest is added because it reflects the claim on assets consolidated into the firm in question. Value of associate companies is subtracted because it reflects the claim on assets consolidated into other firms. EV should also include such special components as unfunded pension liabilities, employee stock options, environmental provisions, abandonment provisions, and so on, since they also reflect claims on the company.
Unternehmenswert von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu 180 Life Sciences
Was macht 180 Life Sciences?
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Unternehmen mit unternehmenswert ähnlich 180 Life Sciences
- Lamtex hat Unternehmenswert von $8.57M
- Enertime SA hat Unternehmenswert von $8.58M
- Invex Therapeutics Ltd hat Unternehmenswert von $8.58M
- Invex Therapeutics Ltd hat Unternehmenswert von $8.58M
- KalNorth Gold Mines hat Unternehmenswert von $8.59M
- SportsHero hat Unternehmenswert von $8.59M
- 180 Life Sciences hat Unternehmenswert von $8.60M
- IDT Australia hat Unternehmenswert von $8.60M
- InsuraGuest Technologies hat Unternehmenswert von $8.60M
- Inventus Mining hat Unternehmenswert von $8.60M
- Virat Crane Industries hat Unternehmenswert von $8.60M
- Black Swan Graphene Inc hat Unternehmenswert von $8.60M
- QMC Quantum Minerals Corp hat Unternehmenswert von $8.61M